Physician
Pediatric Hematology & Oncology
Dr. E A. Kolb, MD
|
|
Give Review
Doctor E A. Kolb, MD works in the field of Pediatric Hematology & Oncology. He attended Jefferson Medical College. Kolb is also published. He has 79 publications published. The lastest publication: "Vibrio fluvialis: an underrecognized enteric pathogen in infants?'
Publications
- Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.
- Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
- Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
- Challenges in Converting Acute Myeloid Leukemia (AML) Genomics Into AML Clinical Trials.
- A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase ...
- Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®) ) by the Pediatric Preclinical Testing Program (PPTP).
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program.
- Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
- Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.
- Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
- Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
- Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
- Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
- Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program.
- Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
- Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.
- Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
- Initial Testing (Stage 1) of Eribulin, a Novel Tubulin Binding Agent, by the Pediatric Preclinical Testing Program.
- Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
- Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.
- Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
- Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
- Initial testing (stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
- Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts.
- Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.
- Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.
- Initial testing of lenalidomide by the pediatric preclinical testing program.
- Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.
- Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
- Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
- Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.
- Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
- Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.
- Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
- Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus.
- R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
- Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
- Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
- Initial testing of topotecan by the pediatric preclinical testing program.
- Moving towards non-invasive assessments of prognosis in osteosarcoma.
- Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.
- Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.
- Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
- Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
- Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.
- Initial testing of aplidin by the pediatric pre-clinical testing program.
- Development of IGF-IR Inhibitors in Pediatric Sarcomas.
- Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
- Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
- Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
- Initial testing of dasatinib by the pediatric preclinical testing program.
- Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.
- Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
- Initial testing of cisplatin by the pediatric preclinical testing program.
- Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
- Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
- The pediatric preclinical testing program: description of models and early testing results.
- Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
- The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.
- Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia.
- Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway.
- Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
- Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
- Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
- Ecteinascidin-743 inhibits activated but not constitutive transcription.
- Vibrio fluvialis: an underrecognized enteric pathogen in infants?
- Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
- Past, present and future of therapies in pediatric sarcomas.
- Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program.
- A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.
- The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
- Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of t...
- Progress of oncolytic viruses in sarcomas.
- The neuroradiological findings in a case of Revesz syndrome.
- Oncolytic viruses for potential osteosarcoma therapy.
- Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma.
- Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Schools
Thomas Jefferson University
Ny and Presby Hospital
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Select
- Personal Choice PPO
- Great West Healthcare-Cigna PPO
- Coventry Health America PPO
- Southern Health PPO
- Coventry Health Care of Delaware PPO
- First Health (Coventry Health Care) PPO
- Advance EPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- MultiPlan PPO
- Freedom Plan
- QualCare HMO
- QualCare PPO
Education
-
New York Presbyterian Hospital -
Jefferson Medical College
Hospital
-
Thomas Jefferson University Hospital
Helpful Reviews
Similar Doctors
|
Dr. Maureen F. Edelson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Gregory Griffin, LCSW
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa Wray, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suba Krishnan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Emi H. Caywood, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Gregory C. Griffin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy K. Barone, MD
This Doctor is OpenDoctor Recommended.
|